Joseph Young Sells 15,000 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph Young sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Vera Therapeutics Stock Down 0.1%

NASDAQ:VERA opened at $28.35 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The firm’s 50-day moving average price is $27.97 and its 200-day moving average price is $24.33. The company has a market capitalization of $1.81 billion, a PE ratio of -7.11 and a beta of 1.22. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.27.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period last year, the company earned ($0.85) EPS. On average, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Vera Therapeutics by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after acquiring an additional 377,783 shares during the period. Deerfield Management Company L.P. grew its position in shares of Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after purchasing an additional 293,040 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Vera Therapeutics by 6.3% during the third quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock worth $92,720,000 after purchasing an additional 189,545 shares in the last quarter. Vestal Point Capital LP raised its stake in Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the period. Finally, Integral Health Asset Management LLC lifted its holdings in Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after purchasing an additional 550,000 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright lifted their price objective on Vera Therapeutics from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Bank of America initiated coverage on shares of Vera Therapeutics in a report on Thursday, October 16th. They set a “buy” rating and a $48.00 price target on the stock. Wolfe Research reiterated a “peer perform” rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Thursday, September 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.90.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.